Literature DB >> 24509751

Biologic product identification and US pharmacovigilance in the biosimilars era.

Thomas Felix1, Torbjörn T Johansson2, Jodi A Colliatie3, Michael R Goldberg3, Andrew R Fox4.   

Abstract

Mesh：

Substances：

Year:  2014        PMID： 24509751     DOI： 10.1038/nbt.2823

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  1 in total

1.  Evaluating the completeness and accuracy of MedWatch data.

Authors:  Kenneth A Getz; Stella Stergiopoulos; Kenneth I Kaitin
Journal:  Am J Ther       Date:  2014 Nov-Dec       Impact factor: 2.688
  1 in total
  2 in total

Review 1.  The Diversity of Biosimilar Design and Development: Implications for Policies and Stakeholders.

Authors:  Gustavo Grampp; Sundar Ramanan
Journal:  BioDrugs       Date:  2015-12       Impact factor: 5.807

2.  Pharmacovigilance Considerations for Biosimilars in the USA.

Authors:  Gustavo Grampp; Thomas Felix
Journal:  BioDrugs       Date:  2015-10       Impact factor: 5.807
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.